Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven for Parenteral Nutrition Associated Liver Disease
NCT01194063Phase 3Completed
- Sponsor
- Kapiolani Medical Center for Women & Children
- Start
- Oct 2010
- Primary completion
- Nov 2018
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in Parenteral Nutrition Associated Liver Disease (PNALD), sponsored by Kapiolani Medical Center for Women & Children. Primary endpoint: Improving cholestasis at 4 months. Started Oct 2010; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD)
Beyond the preview
Go deeper on NCT01194063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01194063.